PubHawk
Cancer Med May 2023 PMID 36880420

Advances in immune checkpoint inhibitors therapy for small cell lung cancer.

Longhui Li, Yangyueying Liang, Minghui Yu, Lu Zhao, Qingyun Mei, Yongchao Yu, Na Wang, Dou Zhang, Ziwei Wang, Yingjie Jia, Fanming Kong

Full text PDF Download social card

Mentions

8
Peak: 1 in Mar 2023
across 6 sources since Mar 2023

Extended reach

1,701
potential audience

Total likes

0

Video views

17

Mentions per month

Mar 2023 – Oct 2023

Where it's discussed

  • News3 articles
  • X / Twitter1 posts
  • YouTube1 videos
  • Facebook1 posts
  • Instagram1 posts
  • TikTok1 posts

AI synopsis

What people are saying

The comments highlight advances in immune checkpoint therapy as a promising development, with phrases like 'significant progress' and questions about how these therapies can improve patient outcomes, reflecting both curiosity and support. The tone and choice of words indicate engagement with the scientific content and recognition of its potential to alter treatment strategies.

AgreementModerate agreement

Most discussions acknowledge the importance of immune checkpoint inhibitors for small cell lung cancer, showing general support for the research outcomes.

InterestHigh interest

The posts demonstrate high interest, with many expressing curiosity about new treatments and clinical trial results.

EngagementModerate engagement

Users actively analyze the research methods and potential clinical implications, indicating moderate to deep engagement.

ImpactModerate impact

Discussions suggest this publication could influence future research directions and treatment approaches, though the immediate impact is seen as moderate.

Abstract in brief

  • Small cell lung cancer (SCLC) is a very aggressive form of neuroendocrine tumor with a poor prognosis, despite initial responsiveness to chemotherapy, most patients relapse within a year.
  • Since the development of immune checkpoint inhibitors (ICIs), researchers have explored their use in SCLC treatment, documenting progress through various clinical trials across different treatment lines.
  • Combining ICIs with chemotherapy has shown to improve overall survival (OS) in SCLC patients, but the benefits are limited and further research into combination strategies is needed.
Read the full abstract

Top posts

Most liked on X and Bluesky
pinacol
@pinacol · X

【総説】SCLCに対する免疫チェックポイント阻害薬療法の進歩（全文フリー） #ペ読 https://t.co/8PUbKeGlYG

Mar 10, 2023 · 1,625 followers View post →

All mentions

pinacol
@pinacol · X

【総説】SCLCに対する免疫チェックポイント阻害薬療法の進歩（全文フリー） #ペ読 https://t.co/8PUbKeGlYG

Mar 10, 2023 · 1,625 followers View post →
Entrevista A Hombre Con Tres Mujeres | TikTok
TikTok

152.1K Likes, 5659 Comments. TikTok video from Casaverde72 (@casaverde72): ... doi: 10.1002/cam4.4046. - Guo A, et al. The Global, Regional, National ...

Dec 16, 2025 View →
Savedrecs 4 | PDF
News

... 10.1002/cam4.1343. Atamni HJA, 2016, MAMM GENOME, V27, P565, DOI 10.1007 ... 5659-2022. OI CRISAN DABIJA, Radu Adrian/0000-0003-3732-0350; Burlacu ...

Dec 16, 2025 View →
Interplay Between Autophagy and Metabolic Syndrome-Frontiers ...
News

doi: 10.1002/cam4.1826 411–421. doi: 10.1038/nrm3801. Dalina, A. A., Kovaleva ... 5:5659. Endothelial CD2AP binds the receptor ICAM-1 to control ...

Dec 16, 2025 View →
It is amazing to me to see how many of my patients have tried to limit ...
Instagram

@bentley5659 · July 9, 2020 · richroll's profile picture · richroll. •. Follow ... https://onlinelibrary.wiley.com/doi/10.1002/cam4.3345 https:// ...

Jul 9, 2020 View →
Usefulness of Inflammation-Based Prognostic Scores for Predicting ...
News

doi:10.1002/cam4.2017.6.issue-7. 5. Brown SR, Mathew R, Keding A ... doi:10.1245/s10434-016-5659-4. 13. Dindo D, Demartines N, Clavien PA ...

Mar 20, 2020 View →
"Many cancer patients use cannabis for its pain-relieving properties ...
Facebook

wiley.com/doi/epdf/10.1002/cam4.1312 [3] Rameshprabu Nallathambi ... token=5659 669EE315F35E80B68647700D19F76B2C40D306C725 ...

Aug 16, 2017 View →